OOIR: Observatory of International Research

Papers

(The H4-Index of Liver International is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
TIPS Superiority in Refractory Variceal Haemorrhage: Insights From the TIPSEMS ‐ VB	156
Response to Letter to the Editor: “Chronic Nanoplastic Exposure as a Novel Risk Amplifier for MASLD Progression”	122
Navigating portal hypertension: Unlocking safe passage to healthy pregnancy in EHPVO	104
Importance of gender differences in body composition for liver transplantation and the ‘Sarco‐Model’ study	98
Golexanolone improves fatigue, motor incoordination and gait and memory in rats with bile duct ligation	96
Cardiac Geometry in Cirrhosis: Translation to Public Health and Trial Design	95
Immunogenicity and safety of a third dose of anti‐SARS‐CoV‐2 BNT16b2 vaccine in liver transplant recipients	94
Benefits of Using cT1 for Risk Stratification in MASLD	93
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease	91
Fatty liver disease at the basis of cardiac remodelling and increased heart rate: Insights from the UK Biobank	81
Inside Front Cover	78
Is ageing a problematic hurdle to the efficacy of first‐line atezolizumab plus bevacizumab in hepatocellular carcinoma?	73
Changing epidemiological features of hepatocellular carcinoma: Taiwan's position	65
Letter to the Editor regarding “Long‐term exposure to air pollution and incident non‐alcoholic fatty liver disease and cirrhosis”	65
Different methodologies of protein induced by vitamin K absence or antagonist II in patients without hepatocellular carcinoma	61
Interpreting elevated liver blood test results through a genetic lens: A genome‐wide association study	59
Bringing evidence to the MAFLD‐MASLD debate	57
Liver Disease Complicating Familial Mediterranean Fever: A Study on 66 Patients Out of 533 Adult From the JIR Cohort	55
Clarifying Treatment Pathway Differences and Exposure Bias in the CHIEF Cohort Study	55
On Evaluating GPT ‐4 for CHB Treatment Recommendations: Reproducibility, Vignette Design and Promp	54
Impact of socio‐economic environment on incidence of primary liver cancer in France between 2006 and 2016	52
Determinants of worse liver‐related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort	52
Assessing Treatment Heterogeneity in Predictive Models for HCC Retreatment Response	50
Reply to Reconsidering the Impacts of Steatotic Liver Disease on Adverse Pregnancy Outcomes	50
High disease burden and healthcare resource usage in patients with acute porphyria—A population‐based analysis	49

Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in Young Children With Chronic HCV Infection	49
Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC	44
Primary Biliary Cholangitis Increases Mortality Irrespective of Presence or Absence of Cirrhosis	44
RETRACTION : Interferons α, β, γ Each Inhibit Hepatitis C Virus Replication at the Level of Inte	43
The integrated stress response‐related expression of CHOP due to mitochondrial toxicity is a warning sign for DILI	42
Low‐Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma	42
Reply: Herbal‐Induced Liver Injury Identification and Prevention	42
Correction to ‘Development and Validation of an Image Biomarker to Identify Metabolic Dysfunction Associated Steatohepatitis: MR ‐	42
Loss of Mtarc1 Protects Against Steatotic Liver Disease in Mice	41
Methylprednisolone‐Induced Liver Injury: Insights From FAERS Analysis and Comparison With DILIN Fi	40
Five‐year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study	39
Evaluation of Pathogenic Variants Associated With Monogenic Disorders of Dyslipidemia in Patients With Well Characterised MASLD	38
Causal effect of lower birthweight on non‐alcoholic fatty liver disease and mediating roles of insulin resistance and metabolites	37
Helicobacter pylori‐Associated Surrogate Markers of Intestinal Permeability, Bacterial Translocation and Gut Barrier Damage in Liver Cirrhosis	37
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort	37